biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Should a comparison be made between Bioasis and Denali?

<< Previous

Bullboard Posts

Next >>

Comment by chrispion Dec 22, 2020 1:59pm

162 Views

Post# 32162050

RE:Should a comparison be made between Bioasis and Denali?

worth repeating :)

or haven't read the Corporate Presentation.

Let me help you, firstly, there is absolutely a strong comparison to be made between Bioasis and Denali. Check out page 10 of the Bioasis Corporate Presentation. It clearly demonstrates Bioasis IS comparing itself to Denali. However, the bar graph also clearly demonstrates Bioasis gets 4-6% of the payload into the brain and Denali gets 1.5%.

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports